Nxera Pharma Co., Ltd.
Achieved Second Development Milestone in Metabolic Disease R&D Alliance with Eli Lilly and Company
Nexcera Pharma has achieved milestone payments up to USD 694 million (approx. JPY 110.9 billion) in its alliance with Eli Lilly, already factored into earnings guidance for the fiscal year ending December 2026.
Key Figures
- Maximum Milestone Amount: USD 694 million (approx. JPY 110.9 billion)
- Contract Start Year: 2022
- Impact on FY Dec 2026 Earnings Guidance: Incorporated
AI要約
Overview of R&D Alliance
Nexcera Pharma Co., Ltd. has achieved the second development milestone in its multi-target research, development, and commercialization alliance with Eli Lilly and Company focused on diabetes and metabolic diseases. This milestone was attained through the identification of GPCR-targeted small molecule compounds using the Company's NxWave™ platform and elucidation of the binding sites based on receptor structural analysis. Eli Lilly will assume responsibility for further development and commercialization.
Impact on Performance and Future Outlook
This milestone entitles us to receive up to USD 694 million (approx. JPY 110.9 billion) in milestone payments in addition to tiered royalties based on global sales. The impact on consolidated results for the fiscal year ending December 2026 has already been incorporated in the earnings guidance disclosed on February 13, 2026, and is disclosed timely as a significant progress in the Company's growth strategy.
